{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:07:05Z","timestamp":1793113625536,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023448","name":"Robert Koch-Institut","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pre-exposure prophylaxis (PrEP) with oral emtricitabine\/tenofovir disoproxil (FTC\/TDF) proved highly efficient in preventing HIV. Since 09\/2019, FTC\/TDF-PrEP is covered by health insurances in Germany, if prescribed by licensed specialists. However, methods to longitudinally monitor progress in PrEP implementation in Germany are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Utilizing anonymous FTC\/TDF prescription data from 2017-2021, we developed a mathematical model to disentangle HIV-treatment from PrEP prescriptions, as well as to translate PrEP prescriptions into number of PrEP users. We used the model to estimate past- and future PrEP uptake dynamics, to predict coverage of PrEP needs and to quantify the impact of COVID-19 on PrEP uptake on a national and regional level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified significant (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.01) decelerating effects of the first- and second COVID-19-lockdown on PrEP uptake in 04\/2020 and 12\/2020. We estimated 26,159 (CI: 25,751-26,571) PrEP users by 12\/2021, corresponding to 33% PrEP coverage of people in need. We projected 64,794 (CI: 62,956-66,557) PrEP users by 12\/2030, corresponding to 81% PrEP coverage. We identified profound regional differences, with high PrEP coverage and uptake in metropoles and low coverage in more rural regions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our approach presents a comprehensive solution to monitor and forecast PrEP implementation from anonymous data and highlighted that the COVID-19 pandemic significantly decelerated PrEP uptake in Germany. Moreover, slow PrEP uptake in rural areas indicate that structural barriers in PrEP care, education or information exist that may hamper the goal of ending the AIDS epidemic by 2030.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-024-19198-y","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T05:01:57Z","timestamp":1719291717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dynamics of HIV PrEP use and coverage during and after COVID-19 in Germany"],"prefix":"10.1186","volume":"24","author":[{"given":"Daniel","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Duport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Iannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"von Kleist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"19198_CR1","unstructured":"IN DANGER: UNAIDS Global AIDS Update 2022. Geneva: Joint United Nations Programme on HIV\/AIDS; 2022. Licence: CC BY-NC-SA 3.0 IGO. 2022. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2022-global-aids-update_en.pdf."},{"issue":"5","key":"19198_CR2","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, Crane H, Monforte AdA, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. The Lancet HIV. 2023;10(5):e295\u2013307.","journal-title":"The Lancet HIV."},{"issue":"12","key":"19198_CR3","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MA, et al. Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med. 2021;27(12):2085\u201398.","journal-title":"Nat Med"},{"issue":"10","key":"19198_CR4","doi-asserted-by":"publisher","first-page":"e0276404","DOI":"10.1371\/journal.pone.0276404","volume":"17","author":"EA Tarimo","year":"2022","unstructured":"Tarimo EA, Ambikile J, Munseri P, Bakari M. Personal experiences following acquiring HIV infection while volunteering in phase I\/II HIV vaccine trials: A qualitative study from Tanzania. PLoS ONE. 2022;17(10):e0276404.","journal-title":"PLoS ONE"},{"issue":"151","key":"19198_CR5","doi-asserted-by":"publisher","first-page":"151ra25","DOI":"10.1126\/scitranslmed.3004006","volume":"4","author":"PL Anderson","year":"2012","unstructured":"Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra25\u2013ra25.","journal-title":"Sci Transl Med"},{"issue":"23","key":"19198_CR6","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"J Molina","year":"2015","unstructured":"Molina J, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237\u201346.","journal-title":"N Engl J Med"},{"issue":"8","key":"19198_CR7","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","volume":"9","author":"J-M Molina","year":"2022","unstructured":"Molina J-M, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. The Lancet HIV. 2022;9(8):e554\u201362.","journal-title":"The Lancet HIV"},{"key":"19198_CR8","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2772765\/v1","volume-title":"Synthesis of protective PrEP adherence levels in cisgender women using convergent clinical and bottom-up modelling","author":"M von Kleist","year":"2023","unstructured":"von Kleist M, Zhang L, Iannuzzi S, Chaturvedula A, Haberer J, Hendrix C. Synthesis of protective PrEP adherence levels in cisgender women using convergent clinical and bottom-up modelling. 2023."},{"key":"19198_CR9","unstructured":"Heiden Mad, Marcus U, Kollan C, Schmidt D, Koppe U, Gunsenheimer-Bartmeyer B, Bremer V. Sch\u00e4tzung der Anzahl von HIV-Neuinfektionen im Jahr 2021 und der Gesamtzahl von Menschen, die Ende 2021 mit HIV in Deutschland leben. Epidemiologisches Bulletin 2022;47\/2022."},{"key":"19198_CR10","unstructured":"Bundesministerium f\u00fcr Gesundheit. Terminservice- und Versorgungsgesetz (TSVG). 2019:Artikel 1 Nr. 9. Available from: https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Gesetze_und_Verordnungen\/GuV\/T\/TSVG_BGBL.pdf."},{"key":"19198_CR11","unstructured":"Anlage 33 zum Bundesmantelvertrag-\u00c4rzte (BMV-\u00c4) Vereinbarung \u00fcber die HIV-Pr\u00e4expositionsprophylaxe zur Pr\u00e4vention einer HIV-Infektion gem\u00e4\u00df\u00a7 20j SGB V vom 24. 2019. Available from: https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/aerztliche_versorgung\/bundesmantelvertrag_1\/bmv_anlagen\/BMV-Ae_Anlage_33_PreP_24-7-2019.pdf . 2021 Oct 6."},{"key":"19198_CR12","doi-asserted-by":"publisher","first-page":"100486","DOI":"10.1016\/j.lanepe.2022.100486","volume":"22","author":"SB de Gage","year":"2022","unstructured":"de Gage SB, Desplas D, Dray-Spira R. Roll-out of HIV pre-exposure prophylaxis use in France: A nationwide observational study from 2016 to 2021. Lancet Reg Health Eur. 2022;22:100486.","journal-title":"Lancet Reg Health Eur"},{"issue":"12","key":"19198_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annepidem.2018.06.009","volume":"28","author":"PS Sullivan","year":"2018","unstructured":"Sullivan PS, Giler RM, Mouhanna F, Pembleton ES, Guest JL, Jones J, et al. Trends in the use of oral emtricitabine\/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012\u20132017. Ann Epidemiol. 2018;28(12):833\u201340.","journal-title":"Ann Epidemiol"},{"issue":"2","key":"19198_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0033354920904085","volume":"135","author":"NW Furukawa","year":"2020","unstructured":"Furukawa NW, Smith DK, Gonzalez CJ, Huang Y-LA, Hanna DB, Felsen UR, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016\u2013June 2018. Public Health Rep. 2020;135(2):202\u201310.","journal-title":"Public Health Rep"},{"issue":"46","key":"19198_CR15","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.15585\/mmwr.mm6446a5","volume":"64","author":"FN Laufer","year":"2015","unstructured":"Laufer FN, O\u2019Connell DA, Feldman I, Zucker HA. Vital signs: increased medicaid prescriptions for preexposure prophylaxis against HIV infection\u2014New York, 2012\u20132015. Morb Mortal Wkly Rep. 2015;64(46):1296\u2013301.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"2","key":"19198_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/cid\/ciw701","volume":"64","author":"H Wu","year":"2017","unstructured":"Wu H, Mendoza MC, Y-lA H, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons\u2014United States, 2010\u20132014. Clin Infect Dis. 2017;64(2):144\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"19198_CR17","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1093\/cid\/ciac038","volume":"75","author":"YLA Huang","year":"2022","unstructured":"Huang YLA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of coronavirus disease 2019 (COVID-19) on human immunodeficiency virus (HIV) pre-exposure prophylaxis prescriptions in the United States\u2014a time-series analysis. Clin Infect Dis. 2022;75(1):e1020\u20137.","journal-title":"Clin Infect Dis"},{"key":"19198_CR18","unstructured":"Statistisches Bundesamt (DESTATIS). Krankenversicherungsschutz. 2023 [Available from: https:\/\/www.destatis.de\/DE\/Themen\/Arbeit\/Arbeitsmarkt\/Qualitaet-Arbeit\/Dimension-2\/krankenversicherungsschutz.html."},{"key":"19198_CR19","doi-asserted-by":"crossref","unstructured":"Schmidt D. Projekthomepage: Evaluation der Einf\u00fchrung der HIV-Pr\u00e4expositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (EvE-PrEP): Robert Koch-Institut; 2022 Available from: \nhttps:\/\/www.rki.de\/eve-prep\n.","DOI":"10.1007\/s00103-023-03733-0"},{"key":"19198_CR20","doi-asserted-by":"crossref","unstructured":"Schmidt D, Kollan C, Schewe K, Hanhoff N, R\u00fcsenberg R, Friebe M, et al. Evaluation der Einf\u00fchrung der HIV-Pr\u00e4expositionsprophylaxe als Leistung der gesetzlichen Krankenversicherung (EvE-PrEP). Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz. 2023:1\u201311.","DOI":"10.1007\/s00103-023-03733-0"},{"key":"19198_CR21","unstructured":"Schmidt D. Projekthomepage: Surveillance der Versorgung mit der HIV-Pr\u00e4expositionsprophylaxe innerhalb der GKV in Deutschland (PrEP-Surv): Robert Koch Institute; 2022. Available from: https:\/\/www.rki.de\/hiv-prepsurv"},{"key":"19198_CR22","doi-asserted-by":"publisher","unstructured":"Marcus U, Schmidt D, Schink SB, et al. Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use in Germany among men who have sex with men. J Public Health (Berl.) 2023;31:1505\u201321. https:\/\/doi.org\/10.1007\/s10389-022-01699-y.","DOI":"10.1007\/s10389-022-01699-y"},{"key":"19198_CR23","doi-asserted-by":"publisher","unstructured":"Schmidt D. PrEP in Deutschland - Ergebnisse aus PrEP-Evaluation und nationaler PrEP-Surveillance. 11. Deutsch-\u00d6sterreichischer-AIDS-Kongress (D\u00d6AK 2023); 23.3.-25.3.2023; Bonn. 2023. https:\/\/doi.org\/10.1111\/hiv.13464.","DOI":"10.1111\/hiv.13464"},{"key":"19198_CR24","first-page":"3","volume":"7","author":"D Schmidt","year":"2023","unstructured":"Schmidt D, Schikowski T, Friebe M, Kollan C, Bremer V, Bartmeyer B, et al. Surveillance der Versorgung mit der HIV-Pr\u00e4expositionsprophylaxe in Deutschland \u2013 Ergebnisse der halbj\u00e4hrlichen Befragung in HIV-Schwerpunkteinrichtungen. Epid Bull. 2023;7:3\u201313.","journal-title":"Epid Bull"},{"key":"19198_CR25","doi-asserted-by":"publisher","unstructured":"Schmidt D, Kollan C, Bartmeyer B, et al. Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. Infection. 2023;51:665\u201378. https:\/\/doi.org\/10.1007\/s15010-022-01919-3.","DOI":"10.1007\/s15010-022-01919-3"},{"issue":"2021","key":"19198_CR26","first-page":"3","volume":"44","author":"D Schmidt","year":"2021","unstructured":"Schmidt D, Schikowski T, Friebe M, Kollan C, Bartmeyer B, Bremer V, et al. PrEP-Evaluation EvE-PrEP \u2013 Ergebnisse einer Befragung zum PrEP-Versorgungsgeschehen in HIV-Schwerpunktzentren des dagn\u00e4-Netzwerks. Epidemiolog Bull. 2021;44(2021):3\u201312.","journal-title":"Epidemiolog Bull"},{"key":"19198_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-9-181","volume":"9","author":"U Marcus","year":"2009","unstructured":"Marcus U, Schmidt AJ, Kollan C, Hamouda O. The denominator problem: estimating MSM-specific incidence of sexually transmitted infections and prevalence of HIV using population sizes of MSM derived from Internet surveys. BMC Public Health. 2009;9:1\u201311.","journal-title":"BMC Public Health"},{"issue":"8","key":"19198_CR28","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1016\/S2352-3018(21)00127-2","volume":"8","author":"R Schaefer","year":"2021","unstructured":"Schaefer R, Schmidt H-MA, Ravasi G, Mozalevskis A, Rewari BB, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8(8):e502\u201310.","journal-title":"Lancet HIV"},{"key":"19198_CR29","doi-asserted-by":"crossref","unstructured":"Wang H, Popping S, van de Vijver D, Jonas KJ. Epidemiological impact and cost-effectiveness of expanding formal PrEP provision to PrEP-eligible MSM expressing PrEP-intention in the Netherlands. medRxiv. 2023:2023.06. 19.23291600.","DOI":"10.1101\/2023.06.19.23291600"},{"issue":"33\u201334","key":"19198_CR30","first-page":"545","volume":"114","author":"J Haversath","year":"2017","unstructured":"Haversath J, G\u00e4rttner KM, Kliem S, Vasterling I, Strauss B, Kr\u00f6ger C. Sexual behavior in Germany: results of a representative survey. Dtsch Arztebl Int. 2017;114(33\u201334):545.","journal-title":"Dtsch Arztebl Int"},{"key":"19198_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-016-3149-z","volume":"16","author":"CH Mercer","year":"2016","unstructured":"Mercer CH, Prah P, Field N, Tanton C, Macdowall W, Clifton S, et al. The health and well-being of men who have sex with men (MSM) in Britain: Evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). BMC Public Health. 2016;16:1\u201316.","journal-title":"BMC Public Health"},{"key":"19198_CR32","unstructured":"Centers for Disease Control and Prevention (CDC). Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data\u2014United States and 6 Dependent Areas, 2021: Tables 2023. Available from: https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance\/vol-28-no-4\/content\/tables.html."},{"key":"19198_CR33","unstructured":"Schmidt D, Bartmeyer B, Bremer V, Friebe M, Schikowski T, Schink SB, et al. Abschlussbericht - Evaluation der Einf\u00fchrung der HIV-Pr\u00e4expositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (EvE-PrEP). Berlin; 2022;22:06.2022."},{"key":"19198_CR34","volume-title":"Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance: technical brief","author":"World Health Organization (WHO)","year":"2022","unstructured":"World Health Organization (WHO). Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance: technical brief. 2022."},{"key":"19198_CR35","unstructured":"Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage IX (Festbetragsgruppenbildung) und Anlage X (Vergleichsgr\u00f6\u00dfenaktualisierung) \u2013 Kombinationen zweier Nukleos(t)id-Analoga, Gruppe 1, in Stufe 3. Vom 20. Februar 2020. BAnz AT 09042020 B4. Available from: https:\/\/www.g-ba.de\/beschluesse\/."},{"issue":"1","key":"19198_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-021-07390-4","volume":"22","author":"M Lottes","year":"2022","unstructured":"Lottes M, Bremer V, Prugger C, Kollan C, Schmidt D. Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019. BMC Health Serv Res. 2022;22(1):1\u20139.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"19198_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00103-021-03312-1","volume":"64","author":"R R\u00fcsenberg","year":"2021","unstructured":"R\u00fcsenberg R, Baumgarten A, Mauss S, Gradl G, Schulz M, Bartmeyer B, et al. Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV-Infektion. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz. 2021;64(5):625\u201334.","journal-title":"Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz."},{"issue":"2","key":"19198_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.24945\/MVF.02.19.1866-0533.2083","volume":"12","author":"E Z\u00f6llner","year":"2019","unstructured":"Z\u00f6llner E, Pieloth K. HIV: Von einer t\u00f6dlichen zur chronischen Erkrankung. Monit Versorgungsforsch. 2019;12(2):14\u20135.","journal-title":"Monit Versorgungsforsch"},{"issue":"4","key":"19198_CR39","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a US cohort study. J Int AIDS Soc. 2021;24(4):e25702.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"19198_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WD Venter","year":"2019","unstructured":"Venter WD, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"key":"19198_CR41","unstructured":"Centers for Disease Control and Prevevntion (CDC). 2019 National HIV Surveillance System Reports 2021. Available from: https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2021\/2019-national-hiv-surveillance-system-reports.html."},{"key":"19198_CR42","unstructured":"Centers for Disease Control and Prevention (CDC). PrEP for HIV Prevention in the U.S. 2021. Available from: \nhttps:\/\/www.cdc.gov\/nchhstp\/newsroom\/fact-sheets\/hiv\/prep-for-hiv-prevention-in-the-us-factsheet.html\n."},{"issue":"6","key":"19198_CR43","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"19198_CR44","first-page":"3","volume":"5","author":"B Wachtler","year":"2020","unstructured":"Wachtler B, Michalski N, Nowossadeck E, Diercke M, Wahrendorf M, Santos-H\u00f6vener C, et al. Socioeconomic inequalities and COVID-19\u2013A review of the current international literature. J Health Monit. 2020;5(Suppl 7):3.","journal-title":"J Health Monit"},{"issue":"suppl_1","key":"19198_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/eurpub\/ckw222","volume":"27","author":"CL McNamara","year":"2017","unstructured":"McNamara CL, Balaj M, Thomson KH, Eikemo TA, Solheim EF, Bambra C. The socioeconomic distribution of non-communicable diseases in Europe: findings from the European Social Survey (2014) special module on the social determinants of health. European J Public Health. 2017;27(suppl_1):22\u20136.","journal-title":"European J Public Health"},{"issue":"23","key":"19198_CR46","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1056\/NEJMsa0707519","volume":"358","author":"JP Mackenbach","year":"2008","unstructured":"Mackenbach JP, Stirbu I, Roskam A-JR, Schaap MM, Menvielle G, Leinsalu M, Kunst AE. Socioeconomic inequalities in health in 22 European countries. N Engl J Med. 2008;358(23):2468\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"19198_CR47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/QAI.0000000000002581","volume":"86","author":"WP van Bilsen","year":"2021","unstructured":"van Bilsen WP, Zimmermann HM, Boyd A, Coyer L, van der Hoek L, Kootstra NA, et al. Sexual behavior and its determinants during COVID-19 restrictions among men who have sex with men in Amsterdam. J Acq Imm Defic Syndromes (1999). 2021;86(3):288.","journal-title":"J Acq Imm Defic Syndromes (1999)"},{"issue":"6","key":"19198_CR48","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.3390\/ijerph18063266","volume":"18","author":"AFL de Sousa","year":"2021","unstructured":"de Sousa AFL, de Oliveira LB, Queiroz AAFLN, de Carvalho HEF, Schneider G, Camargo ELS, et al. Casual sex among men who have sex with men (MSM) during the period of sheltering in place to prevent the spread of COVID-19. Int J Environ Res Public Health. 2021;18(6):3266.","journal-title":"Int J Environ Res Public Health"},{"key":"19198_CR49","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.lanepe.2021.100103","volume":"6","author":"A Ullrich","year":"2021","unstructured":"Ullrich A, Schranz M, Rexroth U, Hamouda O, Schaade L, Diercke M, Boender TS. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1\u20132016 - week 32\u20132020. Lancet Reg Health Eur. 2021;6:100103.","journal-title":"Lancet Reg Health Eur."},{"key":"19198_CR50","doi-asserted-by":"publisher","first-page":"1241310","DOI":"10.3389\/fphar.2023.1241310","volume":"14","author":"H Prins","year":"2023","unstructured":"Prins H, D\u00f6rre A, Schmidt D. Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil\/emtricitabine prescriptions during the COVID-19 pandemic. Front Pharmacol. 2023;14:1241310.","journal-title":"Front Pharmacol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-19198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-19198-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-19198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T05:02:40Z","timestamp":1719291760000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-19198-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["19198"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-19198-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3660381\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The recording and use of these data are regulated by the social security law (\u00a7300 SGB V), no ethical approval and informed consent were required since this routinely collected, anonymized secondary data cannot be traced back to individual patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1691"}}